Hepatoprotective drugs associated with a reduced risk of in-hospital mortality
The use of hepatoprotective drugs in the patients with cumulative LBAI tended to attenuate the risk of in-hospital mortality by 38% in the univariate model (crude HR 0.62; 95% CI 0.41 to 0.96; figure 3f; supplementary table 2) compared to their normal LB counterparts, although this association was not significant after adjustment for confounding risk factors such as age, sex, comorbidities, disease severity, lymphocyte count, D-dimer, serum ferritin (adjusted HR 0.67; 95% CI 0.4 to 1.08).